You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pasireotide

Showing 26 - 50 of 80
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cushings Disease Trial in Worldwide (Pasireotide with or without cabergoline)

Terminated
Has Results
  • Cushings Disease
  • Pasireotide with or without cabergoline
  • Birmingham, Alabama
  • +28 more
Aug 28, 2020

Healthy Trial in Nottingham (HTL0030310, Pasireotide, Placebo)

Completed
  • Healthy
  • Nottingham, United Kingdom
    Quotient Sciences
Oct 26, 2020

Pancreatic Cancer Trial in Tampa (SOM 230 LAR, Gemcitabine)

Completed
  • Pancreatic Cancer
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Sep 25, 2020

Acromegaly Trial in Worldwide (Pasireotide LAR)

Completed
Has Results
  • Acromegaly
  • Pasireotide LAR
  • Caba, Buenos Aires, Argentina
  • +49 more
Dec 6, 2019

Acromegaly, Pituitary Gigantism Trial in Japan (Pasireotide LAR)

Completed
Has Results
  • Acromegaly
  • Pituitary Gigantism
  • Pasireotide LAR
  • Nagoya, Aichi, Japan
  • +26 more
Aug 12, 2019

Non-functioning Pituitary Adenoma Trial in Brazil (Pasireotide LAR)

Completed
Has Results
  • Non-functioning Pituitary Adenoma
  • Pasireotide LAR
  • Fortaleza, CE, Brazil
  • +6 more
Apr 24, 2019

Neuroendocrine Tumors Trial in Bad Berka, Berlin, Muenster (RAD001, SOM230)

Completed
  • Neuroendocrine Tumors
  • Bad Berka, Germany
  • +2 more
Apr 13, 2019

Cushing's Disease, Acromegaly Trial in Worldwide (Pasireotide s.c., Sitagliptin, Liraglutide)

Completed
Has Results
  • Cushing's Disease
  • Acromegaly
  • Pasireotide s.c.
  • +5 more
  • Multiple Locations, California
  • +42 more
May 7, 2019

Neuroendocrine Tumors Trial in Atlanta (Pasireotide, Sir-sphere Radioembolization, Everolimus)

Completed
  • Neuroendocrine Tumors
  • Pasireotide
  • +2 more
  • Atlanta, Georgia
    Emory University Winship Cancer Institute
Oct 16, 2018

Cushing Disease Trial in France (Patient group, Remission control group, Bilateral surrenalectomy control group)

Recruiting
  • Cushing Disease
  • Patient group
  • +2 more
  • Caen, France
  • +6 more
Dec 16, 2021

Hypoglycemia, Reactive Trial in Køge (Pasireotide 0.3 MG/ML, Meal tolerance test (MTT))

Unknown status
  • Hypoglycemia, Reactive
  • Pasireotide 0.3 MG/ML
  • Meal tolerance test (MTT)
  • Køge, Denmark
    Zealand University Hospital
Jul 2, 2018

Somatostatin Receptors and GH Receptor Expression on Bone of

Completed
  • Evaluation of the Expression of Somatostatin Receptors and GH Receptor on Bone of Acromegalic Patients
  • Trans-sphenoidal surgery
  • Roma, Italy
    Fondazione Policlinnico Gemelli IRCCS
Apr 6, 2023

Castrate Resistant Prostate Cancer, Chemo Naive Prostate Cancer, Prostate Cancer Trial in New Haven, Philadelphia (Pasireotide,

Terminated
Has Results
  • Castrate Resistant Prostate Cancer
  • +2 more
  • Pasireotide
  • +2 more
  • New Haven, Connecticut
  • +1 more
Apr 23, 2018

Cushings Disease Trial in Los Angeles (R-roscovitine)

Terminated
Has Results
  • Cushings Disease
  • Los Angeles, California
    Cedars-Sinai Medical Center
Nov 1, 2021

Neuroendocrine Tumors Trial in Milan (Lanreotide and Metformin)

Active, not recruiting
  • Neuroendocrine Tumors
  • Lanreotide and Metformin
  • Milan, Italy
    NationalCIMilan
Jun 4, 2021

Cluster Headache - Episodic and Chronic Trial in Germany, United Kingdom, United States (SOM230, Placebo)

Terminated
Has Results
  • Cluster Headache - Episodic and Chronic
  • Culver City, California
  • +3 more
Dec 9, 2020

Ectopic ACTH Syndrome Trial in Los Angeles (Pasireotide)

Withdrawn
  • Ectopic ACTH Syndrome
  • Pasireotide
  • Los Angeles, California
    Cedars-Sinai Medical Center
Jan 24, 2018

Gonadotroph Adenomas Trial in Philadelphia (pasireotide LAR)

Terminated
Has Results
  • Gonadotroph Adenomas
  • pasireotide LAR
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Oct 20, 2017

Cushing's Disease Trial in Worldwide (Pasireotide sub-cutaneous)

Completed
Has Results
  • Cushing's Disease
  • Pasireotide sub-cutaneous
  • Peoria, Arizona
  • +64 more
May 24, 2018

Cushing Disease Trial (Pasireotide 0.6 MG/ML)

Completed
  • Cushing Disease
  • Pasireotide 0.6 MG/ML
  • (no location specified)
Oct 25, 2017

Hypoglycemia, Obesity, Surgery Trial (drug, device, dietary supplement)

Completed
  • Hypoglycemia
  • +2 more
  • Glucobay (acarbose)
  • +6 more
  • (no location specified)
Mar 6, 2018

Acromegaly Trial in Worldwide (Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg)

Completed
Has Results
  • Acromegaly
  • Pasireotide
  • +2 more
  • Ann Arbor, Michigan
  • +59 more
Apr 2, 2018

Ductal Carcinoma in Situ Trial in New York (SOM 230 / Pasireotide)

Terminated
Has Results
  • Ductal Carcinoma in Situ
  • SOM 230 / Pasireotide
  • New York, New York
    NYU School of Medicine
Nov 24, 2017

Cushing's Disease Trial in Worldwide (pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg)

Completed
Has Results
  • Cushing's Disease
  • pasireotide LAR
  • +2 more
  • Phoenix, Arizona
  • +81 more
Apr 25, 2018

Uveal Melanoma Trial in New York (RAD001 (Everolimus) and Pasireotide (SOM230) LAR)

Completed
Has Results
  • Uveal Melanoma
  • RAD001 (Everolimus) and Pasireotide (SOM230) LAR
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 6, 2017